Dazamide: Complete Guide on Uses, Side Effects & Dosing

Introduction to Dazamide

Dazamide, also known as acetazolamide, is a potent carbonic anhydrase inhibitor used primarily for the treatment of glaucoma, a group of eye conditions characterized by increased intraocular pressure. It is also used as an adjunctive therapy for various other conditions such as epilepsy, altitude sickness, and edema. Dazamide works by inhibiting the enzyme carbonic anhydrase, which is responsible for the production of hydrogen ions and hydrogen carbonate in the body.

Chemical Composition and Structure

Dazamide has the molecular formula C4H6N4O3S2 and is classified as a sulfonamide drug. Its IUPAC name is 1,3,4-Thiadiazole-2-sulfonamide, and it has several other synonyms, including acetazolamide, Diamox, and Diamox Sequels.

Mechanism of Action

Dazamide is a non-bacteriostatic sulfonamide that inhibits the enzyme carbonic anhydrase, which catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. By inhibiting this enzyme, Dazamide decreases the production of hydrogen ions and hydrogen carbonate, leading to various physiological effects. Source

In the eye, Dazamide reduces the production of aqueous humor, which lowers intraocular pressure, making it effective in treating glaucoma. It also has a diuretic effect, as it inhibits the reabsorption of bicarbonate in the renal tubules, leading to increased excretion of sodium, potassium, and bicarbonate. Additionally, Dazamide stimulates respiration by inducing a mild metabolic acidosis, making it useful in treating altitude sickness and other respiratory disorders.

Medical Uses

Primary Use: Glaucoma Treatment

Dazamide is primarily used in the treatment of open-angle glaucoma, a condition characterized by increased intraocular pressure, which can lead to optic nerve damage and vision loss. By reducing the production of aqueous humor, Dazamide effectively lowers intraocular pressure, making it a valuable treatment option for glaucoma management.

Adjunctive Uses

• Epilepsy Control: Dazamide is sometimes used as an adjunctive therapy in the treatment of refractory seizures, particularly in patients with epilepsy who do not respond adequately to other anticonvulsant medications.
• Diuretic Use: Due to its diuretic properties, Dazamide can be used to reduce edema and fluid retention in various conditions, such as congestive heart failure, nephrotic syndrome, and certain kidney disorders.
• Altitude Sickness: Dazamide‘s ability to stimulate respiration by inducing a mild metabolic acidosis makes it useful in treating acute mountain sickness and high-altitude pulmonary edema.

Pharmacodynamics and Pharmacokinetics

Dazamide is rapidly absorbed after oral administration, with peak plasma concentrations reached within 2-4 hours. It has good bioavailability, with approximately 90% of the administered dose being absorbed. Dazamide is widely distributed throughout the body, including the cerebrospinal fluid (CSF), and it can cross the blood-brain barrier. Source

The elimination half-life of Dazamide ranges from 6 to 9 hours, and it is primarily excreted unchanged in the urine. Dazamide has a duration of action of approximately 8-12 hours, with the onset of action occurring within 1-2 hours after oral administration.

Side Effects and Adverse Reactions

Common side effects of Dazamide include:

• Paresthesia (tingling or numbness in the hands, feet, or mouth)
• Taste disturbances
• Loss of appetite
• Nausea and vomiting
• Diarrhea
• Fatigue
• Headache
• Dizziness

Serious adverse reactions, although rare, may include:

• Severe allergic reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)
• Metabolic acidosis or alkalosis
• Electrolyte imbalances (e.g., hypokalemia, hyponatremia)
• Renal calculi (kidney stones)
• Blood dyscrasias (e.g., aplastic anemia, thrombocytopenia)

Contraindications and Precautions

Dazamide is contraindicated in patients with:

• Known hypersensitivity to sulfonamides
• Marked liver or kidney disease
• Addison’s disease
• Chronic non-purulent angle-closure glaucoma

Precautions should be taken when Dazamide is used in pregnant or lactating women, as it can cross the placental barrier and enter breast milk. It should also be used with caution in patients with electrolyte imbalances, respiratory disorders, or diabetes mellitus.

Drug Interactions

Dazamide may interact with various medications, including:

• Other carbonic anhydrase inhibitors (e.g., topiramate, zonisamide)
• Loop diuretics (e.g., furosemide, bumetanide)
• Anticonvulsants (e.g., phenytoin, carbamazepine)
• Amphetamines
• Cyclosporine
• Quinidine
• Lithium

Concomitant use of Dazamide with these medications may result in additive or synergistic effects, or may alter the efficacy or toxicity of either drug. Close monitoring and dosage adjustments may be necessary.

Dazamide in Veterinary Medicine

Dazamide is also used in veterinary medicine, primarily for the treatment of glaucoma in dogs and cats. It may be used alone or in combination with other medications, such as topical beta-blockers or prostaglandin analogs.

The typical dosage range for dogs is 5-20 mg/kg orally, twice daily, while for cats, the recommended dose is 5-10 mg/kg orally, twice daily. However, dosages should be adjusted based on the individual animal’s response and veterinary guidance.

Dosage and Administration

The dosage of Dazamide varies depending on the condition being treated and the patient’s age, weight, and renal function. In general, the following dosage guidelines are followed:

• Glaucoma: 250-1000 mg/day orally, divided into 1-4 doses
• Epilepsy: 8-30 mg/kg/day orally, divided into 1-4 doses
• Altitude Sickness: 250-500 mg orally, 12-24 hours before ascent, and then every 12-24 hours as needed
• Edema: 250-375 mg orally, once or twice daily

Dazamide is available in various formulations, including tablets, capsules, and injectable solutions, and can be administered orally or intravenously.

Formulations and Brand Names

Dazamide is available under various brand names, including:

• Diamox (tablets, extended-release capsules, injectable solution)
• Diamox Sequels (extended-release capsules)
• Azomide (tablets)
• Ezamide (tablets)

These formulations may vary in strength, release mechanism, and inactive ingredients. It is essential to follow the specific instructions provided with each formulation.

Pharmaceutical Development

Dazamide was first synthesized in 1954 and was introduced into clinical practice in 1959 by Lederle Laboratories (now part of Pfizer). It was initially developed as a diuretic but was later found to be effective in treating various conditions, including glaucoma, epilepsy, and altitude sickness.

Over the years, various formulations and delivery systems of Dazamide have been developed, such as extended-release capsules and ophthalmic solutions. Research is ongoing to explore additional therapeutic applications and improve the drug’s pharmacokinetic profile and safety.

Research and Clinical Studies

Numerous clinical studies have been conducted to evaluate the efficacy and safety of Dazamide in various conditions. Some key research areas include:

• Glaucoma management: Multiple randomized controlled trials have demonstrated the effectiveness of Dazamide in lowering intraocular pressure and slowing the progression of glaucoma. Source
• Epilepsy treatment: Several studies have explored the use of Dazamide as an adjunctive therapy in refractory epilepsy, particularly in patients with focal seizures. Source
• Altitude sickness prevention: Clinical trials have investigated the effectiveness of Dazamide in preventing and treating acute mountain sickness and high-altitude pulmonary edema. Source

Ongoing research efforts are focused on optimizing dosing regimens, identifying potential new indications, and exploring the use of Dazamide in combination with other therapies.

Regulatory Status

Dazamide has been approved for various indications by regulatory agencies around the world, including:

• United States Food and Drug Administration (FDA): Approved for the treatment of glaucoma, edema, and as an adjunctive therapy for epilepsy.
• European Medicines Agency (EMA): Approved for the treatment of glaucoma, edema, and altitude sickness.
• Health Canada: Approved for the treatment of glaucoma and edema.
• Therapeutic Goods Administration (TGA) in Australia: Approved for the treatment of glaucoma, edema, and altitude sickness.

The specific indications and labeling may vary among different countries and regulatory agencies.

Patient Information and Counseling

Patients taking Dazamide should be advised to:

• Take the medication as prescribed and not adjust the dosage without consulting their healthcare provider.
• Stay well-hydrated and monitor for signs of dehydration or electrolyte imbalances.
• Avoid activities that require mental alertness or coordination until the effects of the medication are known.
• Inform their healthcare provider about any other medications they are taking, including over-the-counter drugs and supplements.
• Report any adverse effects or allergic reactions immediately.

Patients should also be advised to follow a balanced diet and maintain regular exercise, as Dazamide may cause potassium depletion.

Comparative Effectiveness

Dazamide is a member of the carbonic anhydrase inhibitor class of drugs, which also includes other agents such as dorzolamide, brinzolamide, and methazolamide. While these drugs share a similar mechanism of action, Dazamide has some unique advantages and disadvantages compared to other members of the class.

Advantages of Dazamide include:

• Systemic efficacy, making it useful for various conditions beyond glaucoma.
• Availability in oral and injectable formulations.
• Longer duration of action compared to some topical carbonic anhydrase inhibitors.

Disadvantages of Dazamide include:

• Higher risk of systemic side effects compared to topical agents.
• Potential for drug interactions due to its broader distribution.
• Contraindicated in patients with sulfonamide sensitivity or severe kidney or liver disease.